Last edition
News about
Heron Therapeutics' ZYNRELEF Receives FDA Approval for Expanded Surgical Indication
The expanded indication covers soft tissue and orthopedic surgical procedures, including foot and ankle, and others avoiding direct exposure to articular cartilage.
Amadix's PreveCol Colorectal Cancer Screening Test Granted FDA Breakthrough Device Designation
This recognition positions Amadix as the first European company to achieve such status for early detection of colorectal cancer.
Pharma Logistics Appoints David A. Hargraves as CEO
In response to the transition, Zaccaro expressed confidence in Hargraves' ability to lead Pharma Logistics into a future marked by growth and innovation.
Sandoz to Bolster Ophthalmology Portfolio Through Acquisition of CIMERLI Biosimilar
The acquisition aligns with Sandoz's dedication to providing expanded treatment options for US patients dealing with vision impairment and loss.
Progeria Research Foundation's Zokinvy Receives Approval in Japan for Progeria Treatment
PRF, a pioneering force in rare disease research, has been at the forefront of Zokinvy clinical trial research since 2007.
Johnson & Johnson's BALVERSA Granted Full FDA Approval for Advanced Urothelial Carcinoma Treatment
This approval is specifically for patients whose disease has progressed after at least one prior systemic therapy, excluding those eligible for and not having received prior PD-1 or PD-L1 inhibitor therapy.
India's Cancer Diagnostics Market Thrives with Technological Advancements and Government Initiatives
The latest market research report, 'India Cancer Diagnostics Market, By Region, Competition Forecast and Opportunities, 2019-2029F,' offers a comprehensive analysis covering key aspects such as product innovation, market drivers, challenges, trends, and regional insights.
MECO Appoints Gregory Queen as New President
Greg will be a member of the Grundfos Water Treatment Solutions Leadership Team.
Sun Pharma to Acquire Taro Pharmaceutical Industries in Definitive Merger Agreement
The agreement outlines Sun Pharma's acquisition of all outstanding ordinary shares of Taro, excluding those already held by Sun Pharma or its affiliates.
Hoth Therapeutics Receives FDA Clearance for Protocol Amendments in HT-001 Clinical Trial
The drug is being developed as a potential treatment for cancer patients experiencing skin toxicities associated with Epidermal Growth Factor Receptor Inhibitors (EGFRI).
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy